Loading
Oral cancer drugs under Part D now have a yearly cap of $2,100, but infused drugs under Part B still carry 20% coinsurance with no limit; a Part B cap would close the biggest hole left in Medicare cancer coverage.
The Inflation Reduction Act capped Part D out-of-pocket spending ($2,000 in 2025, $2,100 in 2026) but left Part B untouched. A patient on an infused checkpoint inhibitor without Medigap or Medicaid owes 20% of the Medicare-approved amount indefinitely. Options include a Part B out-of-pocket cap funded by a premium adjustment, or a guaranteed-issue window for Medigap after a cancer diagnosis so that people can buy the protection that already exists.
Shares Financial toxicity, Prices and value.
Shares Financial toxicity, Prices and value.
Shares Financial toxicity, Prices and value.
Shares Financial toxicity, Prices and value.
Shares Financial toxicity, Prices and value.
Shares Financial toxicity, Prices and value.
Shares Financial toxicity, Prices and value.
Shares Financial toxicity, Prices and value.